Journal of the Chinese Medical Association
Volume 71, Issue 3 , Pages 135-142, March 2008

Comparison of Multiple Reduced-dose and Standard Light Application in Photodynamic Therapy in an Animal Model of Choroidal Neovascularization

  • Shwu-Jiuan Sheu

      Affiliations

    • Department of Ophthalmology, National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
    • Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, R.O.C.
    • Corresponding Author InformationCorrespondence to: Dr Shwu-Jiuan Sheu, Department of Ophthalmology, Kaohsiung Veterans General Hospital, 386, Ta-Chung 1st Road, Kaohsiung 813, Taiwan, R.O.C.
    • ,
  • Youn-Shen Bee

      Affiliations

    • Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, R.O.C.
    • ,
  • Hsiu-Chen Lin

      Affiliations

    • Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, R.O.C.
    • ,
  • Wan-Ling Ho

      Affiliations

    • Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, R.O.C.
    • ,
  • Tsung-Tien Wu

      Affiliations

    • Department of Ophthalmology, National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
    • Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, R.O.C.

Received 4 May 2007; accepted 13 February 2008.

Article Outline

Background

Current photodynamic therapy (PDT) for choroidal neovascularization (CNV) uses a standard radiant exposure of 50 J/cm2 at an irradiance of 600 mW/cm2. However, low-intensity PDT with verteporfin for neovascular tissue has been shown to be more effective than regular high-intensity PDT in an animal model of healthy choroids and corneal neovascularization. Low-intensity PDT also supposedly induces less retinal damage. In this study, we compared the effect of reduced-dose and standard light application PDT in an animal model of CNV.

Methods

A laser injury model was used to induce CNV 3 weeks prior to PDT in brown Norway rats. The CNV lesions were then treated with verteporfin PDT with a dose of verteporfin 6.0 mg/m2 and 5 activating doses of light energy (43, 53, 63, 73 and 83 seconds). Closure of CNV was assessed by fundus fluorescein angiography (FAG). Histopathologic study was done after the last FAG.

Results

PDT with verteporfin significantly reduced the CNV area compared with control non-treated groups 1 week after PDT (p < 0.05). Only those lesions treated for 63 seconds or longer retained their significantly attenuating effect on CNV up to 3 weeks after PDT. There was no significant difference between the inhibition effects induced by reduced-intensity light application for 63 or 73 seconds compared to the standard radiant exposure (83 seconds). Histopathologic study showed that eyes treated with PDT showed significantly less extent and vascularity of CNV lesion than control lesions.

Conclusion

Reduced-intensity PDT with 63-second duration seemed to be as effective as standard dose for CNV suppression. Considering the possible retinal damage following standard PDT, the PDT dose might be adjusted to reduce side effects. Further preclinical study will provide more data on what constitutes appropriate dosimetry for effective and safe PDT in CNV.

Key Words:  age-related macular degeneration , choroidal neovascularization , dose , photodynamic therapy

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Chakravarthy U, Soubrane G, Bandello F, Chong V, Creuzot-Garcher C, Dimitrakos SA, et al  Evolving European guidance on the medical management of neovascular age related macular degeneration . Br J Ophthalmol . 2006;90:1188–1196
  2. Shyong MP , Lee FL , Chen SJ , Tung TH , Tsai DC , Hsu WM . Photodynamic therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration . J Chin Med Assoc . 2005;68:419–424
  3. Avery RL , Pieramici DJ , Rabena MD , Castellarin AA , Nasir MA , Giust MJ . Intravitreal bevacizumab (Avastin) for neovas-cular age-related macular degeneration . Ophthalmology . 2006;113:363–372
  4. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, et al  Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration . Ophthalmology . 2005;112:1048–1053
  5. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration . Retina . 2006;26:495–511
  6. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, et al  Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins . Proc Natl Acad Sci USA . 1995;93:10457–10461
  7. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, et al  Inhibition of vascular endo-thelial growth factor prevents retinal ischemia-associated iris neovascularization . Arch Ophthalmol . 1996;114:66–71
  8. Alon T , Hemo I , Itin A , Pe'er J , Stone J , Keshet E . Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity . Nat Med . 1995;1:1024–1028
  9. Castellarin AA , Nasir MA , Sugino IK , Zarbin MA . Clinicopath-ological correlation of primary and recurrent choroidal neovas-cularisation following surgical excision in age-related macular degeneration . Br J Ophthalmol . 1998;82:480–487
  10. Gragoudas ES , Adamis AP , Cunningham ET , Feinsod M , Guyer DR , VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group  . Pegaptanib for neovascular age-related macular degeneration . N Engl J Med . 2004;351:2805–2816
  11. Zacks DN, Ezra E, Terada Y, Michaud N, Connolly E, Gragoudas ES, et al. Verteporfin photodynamic therapy in the rat model of choroidal neovascularization: angiogenic and histologic characterization . Invest Ophthalmol Vis Sci . 2002;43:2384–2391
  12. Postelmans L , Pasteels B , Coquelet P , El Ouardighi H , Verougstraete C , Schmidt-Erfurth U . Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females . Am J Ophthalmol . 2004;138:803–808
  13. Parodi MB , Pozzo SD , Ravalico G . Retinal pigment epithelium changes after photodynamic therapy for choroidal neovascular-ization in pathological myopia . Acta Ophthalmol Scand . 2007;85:50–54
  14. Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y, et al  Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial . Arch Ophthalmol . 2005;123:448–457
  15. Framme C , Flucke B , Birngruber R . Comparison of reduced and standard light application in photodynamic therapy of the eye in two rabbit models . Graefes Arch Clin Exp Ophthalmol . 2004;244:773–781
  16. Gilpin D . Calculation of a new Meeh constant and experimental determination of burn size . Burns . 1996;22:607–611
  17. Gergakoudi I , Nichols MG , Foster TH . The mechanism of Photofrin photobleaching and its consequences for photody-namic dosimetry . Photochem Photobiol . 1997;65:135–144
  18. Henderson BW , Waldow SM , Mang TS , Potter WR , Malone PB , Dougherty TJ . Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photo-dynamic therapy . Cancer Res . 1985;45:572–576
  19. Sitnik TM , Henderson BW . The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy . Photochem Photobiol . 1998;67:462–466
  20. Henderson BW , Fingar VH . Relationships of tumor hypoxia and response to photodynamic treatment in an experimental mouse tumor . Cancer Res . 1987;47:3110–3114
  21. Treatment of age-related macular degeneration with photody-namic therapy (TAP) study group  . Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin—one-year results of 2 randomized clinical trials: TAP report 1 . Arch Ophthalmol . 1999;117:1329–1345
  22. Tatar O, Adam A, Shinoda K, Stalmans P, Eckardt C, Luke M, et al  Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin pho-todynamic therapy . Am J Ophthalmol . 2006;142:95–104
  23. Lazic R , Gabric N . Intravitreal bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration . Graefes Arch Clin Exp Ophthalmol . 2007;245:68–73
  24. Sheu SJ, Chou LC, Bee YS, Chen JF, Lin HC, Lin PR, et al  Suppression of choroidal neovascularization by intramuscular polymer-based gene delivery of vasostatin . Exp Eye Res . 2005;81:673–679

PII: S1726-4901(08)70005-4

doi:10.1016/S1726-4901(08)70005-4

Journal of the Chinese Medical Association
Volume 71, Issue 3 , Pages 135-142, March 2008

Article Tools